Pfizer (PFE) Capital Expenditures (2009 - 2026)
Pfizer (PFE) posted quarterly Capital Expenditures of $436.0 million for Q1 2026, down 22.7% year-over-year from $564.0 million in Q1 2025, and down 48.4% quarter-over-quarter from $845.0 million in Q4 2025.
Pfizer (PFE) Capital Expenditures (2009 - 2026) Analysis & Trends
Pfizer (PFE) has reported Capital Expenditures for 18 consecutive years, with $436.0 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Capital Expenditures fell 22.7% year-over-year to $436.0 million; the TTM figure through Mar 2026 stood at $2.5 billion (down 35.82% YoY), while the FY2025 annual figure was $2.6 billion, down 9.63% from the prior year.
- Capital Expenditures eased to $436.0 million in Q1 2026 per PFE's latest filing, from $845.0 million in the prior quarter.
- Across five years, Capital Expenditures topped out at $2.0 billion in Q3 2024 and bottomed at $436.0 million in Q1 2026.
- Historically, Capital Expenditures has averaged $837.6 million across 5 years, with a median of $704.0 million in 2024.
- Annual changes were most pronounced in 2023 — Capital Expenditures jumped 77.14% — and 2025, when it tumbled 69.78%.
- Pfizer's Capital Expenditures stood at $751.0 million in 2022, then jumped by 39.01% to $1.0 billion in 2023, then soared by 90.8% to $2.0 billion in 2024, then plunged by 57.58% to $845.0 million in 2025, then plunged by 48.4% to $436.0 million in 2026.
- Business Quant data shows PFE's Capital Expenditures at $436.0 million in Q1 2026, $845.0 million in Q4 2025, and $602.0 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capex (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 652.89 Bn | 632.13 Bn | 17.26 Bn | 1.32 Bn |
| 2 | AbbVie | 470.43 Bn | 463.86 Bn | 12.70 Bn | 322.00 Mn |
| 3 | Merck | 375.74 Bn | 368.60 Bn | 12.21 Bn | 893.00 Mn |
| 4 | Novartis Ag | 302.99 Bn | 295.30 Bn | 11.24 Bn | 321.00 Mn |
| 5 | Astrazeneca | 257.51 Bn | 252.61 Bn | 12.86 Bn | 1.86 Bn |
| 6 | Amgen | 237.06 Bn | 223.07 Bn | 7.24 Bn | 513.00 Mn |
| 7 | Gilead Sciences | 182.88 Bn | 179.70 Bn | 6.22 Bn | 140.00 Mn |
| 8 | Pfizer | 160.14 Bn | 148.44 Bn | 10.94 Bn | 533.00 Mn |
| 9 | Gsk | 106.08 Bn | 101.91 Bn | 8.24 Bn | -440.07 Mn |
| 10 | Sanofi | 55.21 Bn | 47.83 Bn | 10.79 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 28, 2026 | 533.00 Mn |
| Jun 28, 2026 | 533.00 Mn |
| Mar 29, 2026 | 436.00 Mn |
| Mar 29, 2026 | 436.00 Mn |
| Dec 31, 2025 | 845.00 Mn |
| Dec 31, 2025 | 845.00 Mn |
| Sep 28, 2025 | 602.00 Mn |
| Sep 28, 2025 | 602.00 Mn |
| Jun 29, 2025 | 618.00 Mn |
| Jun 29, 2025 | 618.00 Mn |
| Mar 30, 2025 | 564.00 Mn |
| Mar 30, 2025 | 564.00 Mn |
| Sep 29, 2024 | 1.99 Bn |
| Sep 29, 2024 | 1.99 Bn |
| Jun 30, 2024 | 637.00 Mn |
| Jun 30, 2024 | 637.00 Mn |
| Mar 31, 2024 | 704.00 Mn |
| Mar 31, 2024 | 704.00 Mn |
| Dec 31, 2023 | 1.04 Bn |
| Dec 31, 2023 | 1.04 Bn |